SYNTHETIC SMALL INTERFERING RNAS SELECTIVELY SUPPRESS THE EXPRESSION OF PROINFLAMMATORY CYTOKINE GENES (IL-25 AND TSLP) IN EXPERIMENTS IN VITRO



Cite item

Full Text

Abstract

Allergic rhinitis (AR) is an inflammatory disease of the upper respiratory tract (nasal mucosa). AR affects up to 40% of the world's population; in the Russian Federation, the incidence is 18% to 30%, depending on the region. Despite the fact that AR is not a severe pathology, it causes significant economic burden. Another threat associated with this disease is that in 40% of cases, patients with AR eventually develop a more severe disabling pathology - AD. Widespread prevalence and significant economic disadvantages caused by AR determine the importance of developing new ways of prevention and control of this disease, as the existing methods of therapy are insufficient. However, the search for new ways of therapy is impossible without a detailed investigation of the molecular mechanisms of AR pathogenesis. For a long time it was considered that this allergic inflammation is formed by Th2-dependent mechanism with involvement of Th2-lymphocytes, B-cells and eosinophils and pro-inflammatory cytokines: IL-4, IL-5 and IL-13. However, experimental evidence has now accumulated on the role of epithelial cells of the respiratory tract and the proinflammatory cytokines they secrete (IL-25, IL-33 and TSLP) in the pathogenesis of AR and AD. IL-25 has been shown to induce the production of IL-4, IL-5 and IL-13, directing a Th2-type immune response. At the same time, mice with inactivated IL-25 developed barely any Th2-immune response. Inactivation of IL-33 significantly reduces inflammation (mediated by eosinophils) of the respiratory tract. Mice knockout for the cytokine receptor TSLP did not develop nasal hyperreactivity in response to allergen, but the level of nasal mucosal inflammation remained high. Currently, work is actively progressing on the development of new drugs capable of specifically blocking the activity of the listed cytokines; first of all, drugs based on neutralizing monoclonal antibodies. However, there are other technologies that can be used to regulate the activity of genes, such as the technology based on the RNA interference. It can be used to suppress the expression of any gene with a known nucleotide sequence, including genes encoding pro-inflammatory cytokines.

Considering the above, the aim of this work was to design synthetic miRNA molecules and study their ability to specifically block the expression of genes encoding proinflammatory cytokines IL-25 and TSLP in experiments in vitro.

 

About the authors

Mariya Mikhailovna Kaganova

National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia

Email: mariya.kaganova.99@mail.ru
ORCID iD: 0000-0002-2596-5779

Junior Researcher of the Antiviral Immunity Laboratory

Russian Federation

Igor Petrovich Shilovskiy

NRC Institute of Immunology FMBA of Russia, Moscow, Russian Federation

Email: ip.shilovsky@nrcii.ru

PhD, (Biology), Deputy Director on Science and Innovation

Ekaterina Draganovna Timotievich

NRC Institute of Immunology, FMBA of Russia, Moscow, Russian Federation

Email: ed.barvinskaya@nrcii.ru

Junior Researcher of the Antiviral Immunity Laboratory,

Kirill Valerevich Yumashev

NRC Institute of Immunology FMBA of Russia, Moscow, Russian Federation

Email: yumashev.k.98@mail.ru

Junior Researcher of the Antiviral Immunity Laboratory

Danila Alekseevich Gurskii

MVA n. a. K.I. Skryabin, MOA of Russia;
NRC Institute of Immunology FMBA of Russia, Moscow, Russian Federation

Email: gurskiy1412@gmail.com

Student of MVA n. a. K.I. Skryabin, MOA of Russia; Laboratory Assistant of the Antiviral Immunity Laboratory, NRC Institute of Immunology FMBA of Russia, Moscow, Russian Federation

Kamilla Vadimovna Vinogradova

MVA n. a. K.I. Skryabin, MOA of Russia;
NRC Institute of Immunology FMBA of Russia, Moscow, Russian Federation

Email: v.kamilla.v@yandex.com

Student of MVA n. a. K.I. Skryabin, MOA of Russia; Laboratory Assistant of the Antiviral Immunity Laboratory, NRC Institute of Immunology FMBA of Russia, Moscow, Russian Federation

Maiia Vladislavovna Popova

MBF of N.I. Pirogov RNRMU MOH of Russia;
NRC Institute of Immunology FMBA of Russia, Moscow, Russian Federation

Email: mayhemly@mail.ru

Student of MBF of N.I. Pirogov RNRMU MOH of Russia;

Laboratory Assistant of the Antiviral Immunity Laboratory, NRC Institute of Immunology FMBA of Russia, Moscow, Russian Federation

Musa Rakhimovich Khaitov

NRC Institute of Immunology FMBA of Russia;
MBF of N.I. Pirogov RNRMU MOH of Russia, Moscow, Russian Federation

Author for correspondence.
Email: mr.khaitov@nrcii.ru

Corr. Member of RAS, MD, PhD, Prof., Director, NRC Institute of Immunology FMBA of Russia; Head of Immunology Chair, MBF of N.I. Pirogov RNRMU MOH of Russia, Moscow, Russian Federation

References

  1. Bousquet J., Anto J.M., Bachert C., Baiardini I., Bosnic-Anticevich S., Walter Canonica G., Melén E., Palomares O., Scadding G.K., Togias A., Toppila-Salmi S. Allergic rhinitis. Nat. Rev. Dis. Primers, 2020, Vol. 6, no. 1, pp. 95.
  2. Kozulina I.E., Kurbachevа O.M., Ilina N.I. Allergy today. Analysis of new epidemiological data. Russian Journal of Allergy, 2014, Vol.3, pp. 3–10.
  3. Bernstein D.I., Schwartz G., Bernstein J.A. Allergic Rhinitis: Mechanisms and Treatment. Immunol. Allergy Clin. North Am., 2016, Vol. 36, no. 2, pp. 261–78.
  4. Hong H., Liao S., Chen F., Yang Q., Wang D.Y. Role of IL-25, IL-33, and TSLP in triggering united airway diseases toward type 2 inflammation. Allergy., 2020, Vol.75, no. 11, pp. 2794–804.
  5. Wang C., Liu Q., Chen F., Xu W., Zhang C., Xiao W. IL-25 Promotes Th2 Immunity responses in asthmatic mice via nuocytes activation. PLoS One, 2016, Vol. 11, no. 9, pp. 1-13.
  6. Deng C., Peng N., Tang Y., Yu N., Wang C., Cai X., Zhang L., Hu D., Ciccia F., Lu L. Roles of IL-25 in Type 2 Inflammation and Autoimmune Pathogenesis. Front. Immunol., 2021, Vol. 12, pp. 1-8.
  7. Muñoz-Bellido F.J., Moreno E., Dávila I. Dupilumab: A Review of Present Indication. J. investing. Allergol. Clin. Immunol., 2022, Vol. 32, no. 2, pp. 97–115.
  8. Traber G.M., Yu A.M. Special Section on Non-Coding RNAs in Clinical Practice: From Biomarkers to Therapeutic Tools-Minireview RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies. J. Pharmacol. Exp. Ther., 2023, Vol. 384, pp. 133–54.
  9. Nikonova A., Shilovskiy I., Galitskaya M., Sokolova A., Sundukova M., Dmitrieva-Posocco O., Mitin A., Komogorova V., Litvina M., Sharova N., Zhernov Y., Kudlay D., Dvornikov A., Kurbacheva O., Khaitov R., Khaitov M. Respiratory syncytial virus upregulates IL-33 expression in mouse model of virus-induced inflammation exacerbation in OVA-sensitized mice and in asthmatic subjects. Cytokine, 2021, Vol. 138, pp. 1-10.
  10. Elbashir S. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods, 2002, Vol. 26, no. 2, pp. 199–213.
  11. Weber C., Müller C., Podszuweit A., Montino C., Vollmer J., Forsbach A. Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects). Immunology, 2012, Vol. 136, no. 1, pp. 64–77.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) Kaganova M.M., Shilovskiy I.P., Timotievich E.D., Yumashev K.V., Gurskii D.A., Vinogradova K.V., Popova M.V., Khaitov M.R.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № 77 - 11525 от 04.01.2002.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies